Developing a Novel Class of Therapeutics for Muscle Wasting and Frailty

Grant number: 1156562 | Funding period: 2019 - 2022

Completed

Abstract

Effective therapeutics are urgently required to combat skeletal muscle seating associated with chronic disease and aging. This project will conduct a series of studies to establish validity for a novel class of muscle therapeutics designed to prevent the processes that drive protein breakdown in wasting muscles.

Related publications (2)

Proteome-wide systems genetics identifies UFMylation as a regulator of skeletal muscle function

J Molendijk, R Blazev, RJ Mills, YK Ng, KI Watt, D Chau, P Gregorevic, PJ Crouch, JBW Hilton, L Lisowski, P Zhang, K Reue, AJ Lusis, JE Hudson, DE James, MM Seldin, BL Parker

2022-01-01

Improving muscle function has great potential to improve the quality of life. To identify novel regulators of skeletal muscle meta..

Dynamic changes to the skeletal muscle proteome and ubiquitinome induced by the E3 ligase, ASB2β

CA Goodman, JR Davey, A Hagg, BL Parker, P Gregorevic

2021-01-01

Ubiquitination is a posttranslational protein modification that has been shown to have a range of effects, including regulation of..

University of Melbourne Researchers

Paul Gregorevic

Ben Parker